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Abstract
Background.—Clostridium difficile infection (CDI) is a common complication of lung and 
allogeneic hematopoietic cell (HCT) transplant, but the epidemiology and outcomes of CDI after 
transplant are poorly described.
Methods.—We performed a prospective, multicenter study of CDI within 365 days post-
allogeneic HCT or lung transplantation. Data were collected via patient interviews and medical 
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chart review. Participants were followed weekly in the 12 weeks post-transplant and while 
hospitalized and contacted monthly up to 18 months post-transplantation.
Results.—Six sites participated in the study with 614 total participants; 4 enrolled allogeneic 
HCT (385 participants) and 5 enrolled lung transplant recipients (229 participants). 150 CDI cases 
occurred within one year of transplantation; the incidence among lung transplant recipients was 
13.1% and among allogeneic HCTs was 31.2%. Median time to CDI was significantly shorter 
among allogeneic HCT than lung transplant recipients (27 days vs. 90 days; p=0.037). CDI was 
associated with significantly higher mortality from 31–180 days post-index date among the 
allogeneic HCT recipients (Hazard ratio [HR]=1.80; p=0.007). There was a trend towards 
increased mortality among lung transplant recipients from 120–180 days post-index date (HR=4.7, 
p=0.09).
Conclusions.—The epidemiology and outcomes of CDI vary by transplant population; 
surveillance for CDI should continue beyond the immediate post-transplant period.
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Introduction
Clostridium difficile infection (CDI) is the most common infectious cause of healthcare-
associated diarrhea, and risk factors for CDI include antibiotic use, high severity of illness, 
hospitalization, and immunosuppression.1–4 Solid organ and hematopoetic cell transplant 
(HCT) recipients are particularly vulnerable to CDI5. The incidence of CDI among 
allogeneic HCT recipients is high, with an upper estimate of about 30%.6–14 Among solid 
organ transplant recipients, those receiving a lung transplant are at increased risk of CDI, 
with incidence estimates up to 10.8%.15,16 There are few data available on the association 
between transplantation, CDI, and morbidity and mortality. In one study lung transplant 
recipients had greater risk of fulminant colitis compared to non-transplant patients,15 and 
CDI has been associated with increased mortality, particularly during the early post-
transplant period.16,17 In allogeneic HCT recipients, the impact of CDI on mortality is 
unclear. CDI was associated with significantly higher mortality within 180 days of infection 
in two studies,8,18 but Willems at al. found no difference in overall survival between CDI 
cases and controls within two years of transplantation.14 Additionally, variations in study 
design make it difficult to draw firm conclusions about the morbidity and mortality 
associated with CDI after allogeneic HCT and lung transplantation. A better understanding 
of the epidemiology and outcomes of CDI among allogeneic HCT and lung transplant 
recipients would help clinicians treat patients appropriately and help guide infection 
prevention priorities.
The purpose of this study was to describe and compare the incidence and outcomes of CDI 
after allogeneic HCT and lung transplantation, using a multicenter, prospective study design. 
This study was performed in conjunction with the Organ Transplant Infection Prevention 
and Detection Project (OTIP) of the Centers for Disease Control and Prevention (CDC). 
OTIP was a prospective cohort study of all proven and probable invasive fungal infections in 
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patients undergoing allogeneic HCT or lung transplantation (lung and allogeneic HCT 
transplants were selected for analysis because of the higher rates of invasive infections 
among these patients); however, data on other infections, including CDI, were collected as 
well, providing a prospective opportunity to study CDI after lung and allogeneic HCT 
transplant.
Patients and Methods
Six academic medical centers from across the United States participated in the OTIP study. 
Lung transplant recipients were enrolled at five sites, and allogeneic HCT recipients were 
enrolled at four sites, from April 2007 – March 2010. Study participants were enrolled 
during their transplant hospitalization. All participants provided written informed consent. 
Each institution’s institutional review board (IRB) approved the study.
Data collection
Participants underwent clinical assessments at enrollment and weekly during their transplant 
hospitalization. After discharge, participants were contacted by phone weekly up to 12 
weeks post-transplant. After 12 weeks, participants were contacted monthly. If readmitted to 
the hospital, participants were followed weekly until discharge. Participants were followed 
for 2.5 years post-transplant for readmissions, infections, and other outcomes.
Demographic data collected at enrollment included age, sex, race, underlying disease status, 
comorbid disease, type of transplant conditioning, prior chemotherapy/immunosuppressive 
therapies, and transplantation history. Other data collected at enrollment included transplant 
date, donor/recipient CMV status, immunosuppressive medications, and laboratory culture 
and/or test results, including C. difficile test results. The OTIP sites used a variety of CDI 
diagnostic methods during the study period: EIA for toxins A/B (sites B, D, and F), 
cytotoxicity assay (site A), antigen detection or PCR (site C), and GDH plus toxin A/B 
immunoassay (site E). The weekly inpatient and outpatient assessments included patient 
status (home, inpatient, ICU, deceased), mechanical ventilation, current medications, and 
symptoms of infection. All infections were reviewed by Infectious Diseases physicians at 
each site to determine whether the infection was probable, confirmed, or neither. Infections 
were defined according to National Nosocomial Infections Surveillance (NNIS) criteria.19 In 
addition to patient interviews, clinical data were collected prospectively from medical 
records when participants were hospitalized and as available from outpatient clinic records. 
In order to be considered a CDI case, a patient was required to have a positive laboratory test 
for C. difficile and meet the NNIS criteria for gastroenteritis and/or GI tract infection in the 
clinical judgment of the Infectious Disease physician.
Data analyses
CDI cases were included if they occurred any time within 365 days post-transplant. The date 
of first positive laboratory test for C. difficile was used as the index date for analyses. For 
individuals without CDI, an analogous “index” date was randomly selected such that the 
distribution of time from transplant to index date was comparable between CDI cases and 
controls. For patients with >1 transplant during the study period, only the first transplant was 
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included, and patients were censored at the time of second transplant. For this analysis, 
patients were excluded if they were enrolled >7 days post-transplant; prospective data on 
these patients’ pre- and peri-transplant medications were limited. Patients also were 
excluded if they had CDI at the time of transplant. There were 787 patients at the six sites 
enrolled in OTIP; 614 (86%) met all inclusion criteria for this study and were included in 
analyses (Figure 1).
Because the primary outcome of interest in the OTIP study was fungal infections, not CDI, 
limited data on antimicrobial use were available. Thus, analyses focused on demographics 
and outcomes among CDI cases and controls, as well as the general epidemiology of CDI 
among the lung and allogeneic HCT populations. Chi-square and logistic regression were 
used for univariate analyses of categorical variables, as appropriate. Kaplan-Meier plots and 
Cox proportional hazards models with heavy-side functions were used to compare survival 
between CDI cases and controls up to 180 days post-index date. A p-value of 0.05 was 
considered significant in all analyses. Analyses were performed with SPSS, version 23.0 
(Armonk, NY), SAS version 9.2 (Cary, NC), and Stata MP11 (College Station, TX).
Results
A total of 614 patients met inclusion criteria for this study and were included in analyses. 
Lung transplant recipients accounted for 37% of the enrolled patients (N=229) and 
allogeneic HCT recipients accounted for 63% (N=385). 150 patients developed CDI within 
365 days of transplant: 30 (20% of CDIs) among lung transplant recipients (incidence 
13.1%) and 120 (80% of CDIs) among allogeneic HCT recipients (incidence 31.2%).
CDI incidence and time to infection in lung transplant recipients is shown in Table 1 and in 
allogeneic HCTs in Table 2. Site A enrolled 75% of the lung transplant patients. Two sites 
did not have any CDI cases; however, these sites accounted for only 7 transplants. Among 
the 3 sites with CDI cases among lung transplant recipients, site A had a median time to CDI 
of >100 days post-transplant, and time to the single CDI case at site C was 116 days. Site B 
had a much shorter median time to CDI onset of 17 days; at site B, 4 of the 7 CDI cases 
occurred within 20 days of transplant, one occurred at day 90, and 2 occurred >100 days 
post-transplantation. All four sites that enrolled allogeneic HCT patients reported CDI cases, 
with rates ranging from 12.1 – 37.8 CDI per 100 transplants. The median time from 
transplant to CDI ranged from 23–48 days at the 4 sites. Overall, the median time from 
transplant to CDI was shorter among allogeneic HCT recipients than among lung transplant 
recipients (mean = 27 days vs. 90 days; p=0.037; Figure 2).
Patient characteristics associated with CDI after lung transplantation are shown in Table 3 
and after allogeneic HCT are shown in Table 4. Among lung transplant recipients only renal 
failure was significantly associated with CDI, but the numbers were very small. After 
allogeneic HCT, patients with CDI were more likely than uninfected patients to have 
received myeloablative conditioning (61% vs. 38%; p=0.003) and high dose dexamethasone 
(20% vs. 13%; p=0.053). Other cardiovascular disease was the only comorbidity that was 
more common among CDI cases than uninfected HCT recipients (29% vs. 18%; p=0.015), 
and lack of a preexisting comorbid disease was more common among uninfected persons 
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than CDI cases (46% vs. 31%; p=0.004). These relationships were primarily driven by site F, 
which enrolled 50% of the allogeneic HCTs. When site F was removed from analyses, those 
two comorbidity variables were no longer statistically significant (data not shown). By 
contrast, when site F was excluded, myeloablative conditioning remained associated with 
CDI: 86% of cases received myeloablative conditioning vs. 68% of controls (p=0.01). Any 
GVHD in the previous 30 days was more common among CDI cases than controls (23% vs. 
12%; p=0.003). History of a symptomatic urinary tract infection (UTI) in the 30 days before 
the index date was more common among CDI cases than uninfected persons, although the 
difference was of borderline significance (6% vs. 2%, p=0.06).
Among lung transplant recipients, several outcomes (renal failure, BSI, and pneumonia) 
occurred significantly more often among CDI cases than controls in the 30 days post-index 
date (p<0.05 for all; Table 3). Notably, 27% of CDI cases experienced a BSI during the 30 
days post-index date. Among the allogeneic HCT recipients, CDI cases were more likely 
than controls to have any GVHD during the 30 days post-index date (40% vs. 27%; 
p=0.009) (Table 4).
Survival within 180 days after CDI/index date is shown in Figure 3 for lung transplant 
recipients and Figure 4 for allogeneic HCT recipients. Among the lung transplants 
recipients, Cox regression was performed using a heavy-side function to compare mortality 
in the periods 0–30, 31–120, and 121–180 days post-index date. There was no significant 
difference in mortality between CDI cases and controls during the early periods (p=0.98 and 
p=0.23). There was a trend towards increased mortality during the late period among CDI 
cases (Hazard ratio [HR] = 4.7 [95% CI 0.8 – 28.1]; p=0.09) compared to controls. Among 
allogeneic HCT recipients, Cox regression was performed using a heavy-side function to 
determine mortality in the early time period 0–30 days compared to the later time period 31–
180 days post-index date. There was no significant difference in mortality between CDI 
cases and controls during the early period (p=0.52), but mortality was significantly higher 
among CDI cases during the late period (HR=1.80 [95% CI 1.2 – 2.8]; p=0.007) compared 
to controls. Among patients who had died by 180 days post-index date, the underlying 
disease was the cause of death among 27% of allogeneic HCT recipients and 8% of lung 
transplant recipients (p=0.07), and any infection was the cause of death among 21% of the 
allogeneic HCT recipients and 32% of the lung transplant recipients (p=0.21).
Discussion
We compared the epidemiology of CDI in lung transplant and allogeneic HCT recipients. 
Overall, CDI is common in both populations, but the incidence among allogeneic HCT 
recipients is more than two times higher than the incidence of CDI in lung transplant 
recipients.
The epidemiology of CDI after lung transplantation is unclear, and the varying duration of 
follow-up periods in previous studies make it difficult to make comparisons among studies. 
CDI incidence has been estimated in the range of 7–31%,20 and a recent meta-analysis 
reported the pooled prevalence of CDI at 10.8%, but the duration of follow-up varied by 
study.21 Lee et al. and Dallal et al. retrospectively reviewed CDI in lung transplant recipients 
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and reported incidence estimates of >20%-31%, but their analyses covered >10 years.15,16,22 
Gunderson et al reported a lower CDI incidence of 4% within one year of lung 
transplantation compared with our estimate of 13.1%.23 It may be that CDI incidence after 
lung transplantation varies by site due to practice variation, such as differing candidate 
selection, pre-transplant medications, and antimicrobial prophylaxis. Further multicenter 
studies with detailed analyses of risk factors for CDI are needed to address these questions.
We found the median time from transplant to CDI was significantly shorter among 
allogeneic HCT recipients than lung transplant recipients. This is likely due in part to the 
comparatively greater immunosuppression caused by allogeneic HCT conditioning 
regimens, with subsequent prolonged neutropenia, mucositis, and intense antimicrobial 
exposures. Notably, CDI cases among allogeneic HCT recipients were more likely than 
uninfected recipients to have received myeloablative conditioning or high dose 
dexamethasone. The relationship between myeloablative conditioning and CDI in HCT 
recipients has been noted previously.7,11 The underlying biological mechanism behind this 
relationship may be two-fold: myeloablative conditioning increases neutropenia, damages 
the gut mucosa, and is associated with a higher risk of infection in the pre-engraftment 
period (and thus exposure to broad spectrum antimicrobials) versus non-ablative conditions; 
all of these may increase risk of CDI.24 Alternatively, patients who receive myeloablative 
conditioning are more likely to develop diarrhea, and thus more likely to have concurrent 
asymptomatic C. difficile colonization detected. Notably, approximately half of the CDI 
cases in this study occurred >30 days after transplant, suggesting heightened suspicion of 
CDI after allogeneic HCT should continue beyond the immediate post-transplant period.
By comparison, CDI among lung transplant recipients appeared to occur more often in the 
later post-transplant period. The median time to CDI after lung transplant was 90 days, 
although this estimate was primarily driven by the 22 CDI cases at site A. Site B, which 
reported 7 CDI cases, had a median time to CDI of only 17 days. The time to CDI at site B 
appeared bi-modal, with 4 cases within 30 days of transplant and 3 cases from day 90 or 
later. This bi-modal distribution was not evident at site A. This discrepancy may be due to 
different transplant characteristics at the two sites or the small sample size at site B. 
Conversely, it is possible that the lung transplant recipients do have two distinct phases of 
increased risk for CDI: the first immediately following transplantation, and the second in the 
later post-transplant period, resulting from increased or renewed exposure to CDI risk 
factors.
Although antimicrobial usage data were not available for these analyses, we did have 
prospectively collected data on other infections among the transplant recipients, which can 
be used as a surrogate marker for antimicrobial use.25 Additionally, transplant recipients, 
particularly allogeneic HCT, have almost universal exposure to antimicrobials. Among the 
allogeneic HCT recipients, symptomatic UTI was a borderline risk factor for CDI. UTIs are 
often treated with antimicrobials such as fluoroquinolones or cephalosporins, which in turn 
may increase the risk of CDI. An analysis using Medicare data found that UTIs were 
responsible for a greater population attributable risk fraction of CDI cases than any other 
type of infection,25 and they may be a useful antimicrobial stewardship target.
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We found mortality within 180 days of CDI/index date to be significantly higher in the 
allogeneic HCT population but not the lung transplant population. CDI was not associated 
with increased risk of mortality within the first 30 days, but mortality was significantly 
higher among CDI cases from 31–180 days post-index date after allogeneic HCT. This 
finding is different from that of Willems et al., who found no significant difference in 
survival between CDI cases and controls within two years.14 Willems et al. measured 
survival post-HCT, whereas we measured survival in days from CDI or a random index date, 
selected to match the distribution of CDI case onset in the post-HCT period. Among the lung 
transplant recipients, while we did not detect a significant difference in survival at 180 days 
post-CDI/index date, we did find that mortality was marginally higher among CDI cases 
from 120 to 180 days post-index date. Lee et al found mortality among lung transplant 
recipients to be significantly higher after CDI, but their retrospective single-center cohort 
spanned 11 years.16 It may be necessary to follow lung transplant recipients for a longer 
period of time to detect the effect of CDI on mortality. Notably, we found BSI and 
pneumonia to be significantly more frequent in the 30 days after CDI in the lung transplant 
population. It is unclear whether these infections truly result from CDI (or increased 
healthcare exposure caused by CDI), or whether CDI is merely a marker of increasing 
severity of illness. Alternatively, these infections may be a result of microbiome disruption 
associated with CDI; this relationship has been suggested previously with CDI and sepsis.26 
Overall, our data suggest that CDI likely increases mortality in allogeneic HCT recipients, 
while more data are needed on CDI and mortality after lung transplantation.
There are several limitations to this study. Because OTIP’s original focus was on fungal 
infections, not CDI, data on antimicrobials were not collected. Stool samples were not 
collected, so we were unable to evaluate colonization with C. difficile. A variety of C. 
difficile diagnostic tests were used at the participating sites, and these may affect CDI rates.
27
 Additionally, CDI epidemiology and C. difficile diagnosis have continued to change since 
this study was performed; for example, use of molecular diagnostics has increased.27 
Finally, this study was not designed for a detailed analysis of the relationship between CDI 
and GVHD. This relationship is complex, and previous research suggests GVHD, which is 
associated with loss of a healthy gut microbiome, may be both a risk factor and outcome of 
CDI.6,7,24,28–30 This deserves additional study. Despite these limitations, this analysis has 
several strengths, including a prospective, multicenter, cohort study design. Patient 
assessments were performed throughout the study, regardless of whether the participants 
were inpatients or outpatients. The data collected were not limited to medical records and/or 
inpatient hospitalizations, and thus more accurately reflect patients’ clinical status 
throughout the post-transplant period.
While no consensus exists on the exact burden among immunocompromised patients, CDI is 
clearly a problematic infection; the current analysis provides useful data on the 
epidemiology and outcomes of CDI in allogeneic HCT and lung transplant recipients. The 
epidemiology of CDI varies by transplant population, with CDI generally occurring earlier 
post-transplant among allogeneic HCT recipients than lung transplant recipients. Variations 
in CDI incidence among the 6 sites participating in the OTIP study suggest local practices 
may influence risk and outcomes of CDI; this is an important area for future study. CDI may 
be both a cause and indicator of increasing morbidity, particularly among lung transplant 
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recipients. Innovative strategies for CDI prevention and treatment among allogeneic HCT 
and lung transplant recipients are needed.
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Figure 1. 
STROBE diagram of study population.
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Figure 2. 
Comparison of time from transplant to CDI by transplant type. The median time from 
transplant to CDI was 27 days among allogeneic HCT patients and 90 days among lung 
transplant patients (log-rank p=0.037).
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Figure 3. 
Lung transplant recipients: Survival at 180 days after index date, stratified by CDI status.
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Figure 4: 
Allogeneic HCT recipients: Survival at 180 days after index date, stratified by CDI.
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Table 1.
Clostridium difficile infections in 229 lung transplant recipients
Site Enrollment
N (%)
CDI
N (%)
CDI rate per 100
lung transplants
Time to CDI
Median days (range)
A 171 (75) 22 (73) 12.9 105 (4 – 331)
B 30 (13) 7 (23) 23.3 17 (4 – 282)
C 21 (9) 1 (3) 4.8 a(116)
D 2 (1) 0 (0) 0.0 -
E 5 (2) 0 (0) 0.0 -
F NA NA NA -
Total 229 30 13.1 90
a
Median not calculated due to only 1 CDI case patient.
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Table 2.
Clostridium difficile infections in 385 allogeneic HCT transplant recipients
Site Enrollment
N (%)
CDI
N (%)
CDI rate per 100
allogeneic HCTs
Time to CDI
Median days (range)
A NA NA NA NA
B 127 (33) 48 (40) 37.8 48 (1 – 340)
C NA NA NA -
D 9 (2) 2 (2) 22.2 a(6, 50)
E 58 (15) 7 (6) 12.1 47 (1 – 230)
F 191 (50) 63 (53) 33.0 23 (1 – 365)
Total 385 120 31.2 27
a
Median not calculated due to 2 CDI case patients.
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Table 3.
Variables associated with CDI after lung transplantation (N=229; p≤0.20)a
Variable CDI
N (%)
No CDI
N (%)
OR (95% CI) p-value
Risk Factors
 Comorbidities
  Gastroesophageal reflux disease 12 (40) 52 (26) 1.9 (0.9 – 4.2) 0.12
  Other GI disease 5 (17) 15 (8) 2.5 (0.8 – 7.3) 0.15c
 Severity of illness in 30 days before
index date
  ICU admission 11 (37) 48 (24) 1.8 (0.8 – 4.1) 0.14
  Mechanical ventilation 11 (37) 48 (24) 1.8 (0.8 – 4.1) 0.14
  Renal failure 3 (10) 3 (2) 7.3 (1.4 – 37.8) 0.031c
  Symptomatic UTI 2 (7) 3 (2) 4.7 (0.7 – 29.2) 0.13c
Outcomes
 ICU admissionb 3 (10) 8 (4) 2.7 (0.7 – 10.6) 0.16c
 Mechanical ventilation 5 (17) 15 (8) 2.5 (0.8 – 7.3) 0.15c
 Renal failure 3 (10) 4 (2) 5.4 (1.2 – 25.5) 0.050c
 BSI 3 (10) 2 (1) 10.9 (1.7 – 68.5) 0.017c
 Pneumonia 8 (27) 13 (7) 5.2 (1.9 – 13.9) <0.001
 Symptomatic UTI 2 (7) 3 (2) 4.7 (0.7 – 29.2) 0.13c
a
Potential risk factors and outcomes with p>0.20 not included in the table: Age, sex, race, coronary artery disease, congestive heart failure, 
peripheral vascular disease, other cardiovascular disease, COPD, asthma, other pulmonary disease, cirrhosis, chronic renal insufficiency, end state 
renal disease, hemodialysis, peritoneal dialysis, splenectomy, diabetes, autoimmune disease, HIV, HCV, HBV, other comorbid disease, no comorbid 
disease, all pre-transplant medications; dialysis, bloodstream infection, pneumonia, febrile neutropenia, viremia, or respiratory tract infection in 30 
days before index date; dialysis, viremia, and respiratory tract infection in 30 days after index date.
b
ICU admissions at index date are excluded.
c
Fisher’s exact test.
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Table 4.
Variables associated with CDI after allogeneic HCT (N=385; p≤0.20)a
Variable CDI
N (%)
No CDI
N (%)
OR (95% CI) p-value
Risk Factors
 Comorbidities
  Other cardiovascular disease 35 (29) 48 (18) 1.9 (1.1 – 3.1) 0.015
  Diabetes not requiring insulin 9 (8) 8 (3) 2.6 (1.0 – 6.9) 0.047
  No comorbid disease 37 (31) 123 (46) 0.5 (0.3 – 0.8) 0.004
 Pre-transplant medications
  Dexamethasone (high dose) 24 (20) 33 (13) 1.8 (1.0 – 3.1) 0.053
  ATGAM 7 (6) 26 (10) 0.6 (0.2 – 1.4) 0.20
  Other immunomodulator 32 (27) 53 (20) 1.5 (0.9 – 2.4) 0.14
  Fludarabine 41 (34) 115 (43) 0.7 (0.4 – 1.1) 0.09
  Busulfan 67 (56) 171 (65) 0.7 (0.4 – 1.1) 0.10
  Campath 0 (0) 7 (3) Undef 0.10c
 Myeloablative conditioning 33 (61) 55 (38) 2.6 (1.4 – 4.9) 0.003
 Severity of illness in 30 days before
index date
 Symptomatic UTI 7 (6) 5 (2) 3.2 (1.0 – 10.4) 0.055c
 Graft versus host disease (any) 28 (23) 31 (12) 2.3 (1.3 – 4.0) 0.003
Outcomes
 Pneumonia 7 (6) 8 (3) 2.0 (0.7 – 5.6) 0.19
 Viremia 14 (12) 16 (6) 2.1 (1.0 – 4.4) 0.056
 Respiratory tract infection 0 (0) 7 (3) Undef 0.10c
 Graft versus host disease (any) 48 (40) 71 (27) 1.8 (1.2 – 2.9) 0.009
a
Potential risk factors and outcomes with p>0.20 not included in the table: Age, sex, race, coronary artery disease, congestive heart failure, 
peripheral vascular disease, COPD, asthma, other pulmonary disease, GERD, cirrhosis, other GI disease, chronic renal insufficiency, end stage 
renal disease, hemodialysis, peritoneal dialysis, splenectomy, diabetes requiring insuling, autoimmune disease, HIV, HCV, HBV, other disease, 
unmatched HCT donor, unrelated HCT donor, status of malignancy; other pre-transplant medications, ICU admission, mechanical ventilation, renal 
failure, dialysis, bloodstream infection, pneumonia, febrile neutropenia, viremia, or respiratory tract infection in 30 days before index date; ICU 
admission, mechanical ventilation, renal failure, dialysis, bloodstream infection, symptomatic UTI, febrile neutropenia, or respiratory tract infection 
in 30 days after index date.
c
Fisher’s exact test.
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